<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448731</url>
  </required_header>
  <id_info>
    <org_study_id>DERMIA</org_study_id>
    <secondary_id>2017-004413-98</secondary_id>
    <nct_id>NCT03448731</nct_id>
  </id_info>
  <brief_title>Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)</brief_title>
  <acronym>DERMIA</acronym>
  <official_title>Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion CRIS de Investigación para Vencer el Cáncer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion CRIS de Investigación para Vencer el Cáncer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the&#xD;
      potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of&#xD;
      doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth&#xD;
      Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the&#xD;
      present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the&#xD;
      prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with&#xD;
      anti-EGFR in combination with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Actual">April 6, 2020</completion_date>
  <primary_completion_date type="Actual">April 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in the prevention of skin toxicity</measure>
    <time_frame>During 6-week skin treatment</time_frame>
    <description>Monitoring of skin toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients during the treatment</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Change in Dermatology Life Quality Index (DLQI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Number of adverse events per patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Skin Toxicity</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 50 mg p.o. daily during 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 50Mg Tablet</intervention_name>
    <description>Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman at least 18 years old&#xD;
&#xD;
          -  Capable of understanding, signing and dating an informed consent approved by an&#xD;
             Independent Ethics Committee (IEC)&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum in patients with&#xD;
             initially unresectable metastatic (M1) disease&#xD;
&#xD;
          -  Wild-type RAS tumour status confirmed before study inclusion at local institution&#xD;
&#xD;
          -  Patients who have a treatment plan based on FOLFOX + anti-EGFR or FOLFIRI + anti-EGFR,&#xD;
             as first-line treatment of mCRC&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
          -  Adequate bone marrow function: neutrophils ≥1.5 x109/L; platelets ≥100 x109/L;&#xD;
             haemoglobin ≥9 g/dL&#xD;
&#xD;
          -  Hepatic, renal and metabolic function as follows: Total bilirubin count ≤1.5 x upper&#xD;
             limit of normal (ULN), Alanine aminotransferase (ALT) and Aspartate aminotransferase&#xD;
             (AST) &lt;5 x ULN; Renal function, calculated as creatinine clearance or 24-hour&#xD;
             creatinine clearance ≥50 mL/min; Magnesium &gt; lower limit of normal (LLN)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior or concurrent central nervous system (CNS) metastases&#xD;
&#xD;
          -  History of another primary cancer, except: curatively treated in situ cervical cancer,&#xD;
             or curatively resected non-melanoma skin cancer, or other primary solid tumour&#xD;
             curatively treated with no known active disease present and no treatment administered&#xD;
             for ≥5 years before treatment initiation&#xD;
&#xD;
          -  Known hypersensitivity to tetracyclines&#xD;
&#xD;
          -  Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic&#xD;
             colorectal carcinoma&#xD;
&#xD;
          -  Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before&#xD;
             metastatic disease was diagnosed&#xD;
&#xD;
          -  Unresolved toxicities of a previous systemic treatment that, in the opinion of the&#xD;
             investigator, cause the patient unfit for inclusion&#xD;
&#xD;
          -  Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab),&#xD;
             antivascular endothelial growth factor (VEGF) or treatment with small molecule EGFR&#xD;
             inhibitors (e.g., erlotinib)&#xD;
&#xD;
          -  Prior hormonal therapy, immunotherapy or approved or experimental antibody/proteins&#xD;
             ≤30 days before inclusion.&#xD;
&#xD;
          -  Significant cardiovascular disease including unstable angina or myocardial infarction&#xD;
             within 12 months before initiating study treatment or a history of ventricular&#xD;
             arrhythmia&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial&#xD;
             pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT)&#xD;
&#xD;
          -  Treatment for systemic infection within 14 days before the start of study treatment&#xD;
&#xD;
          -  Acute or subacute intestinal occlusion and/or active inflammatory bowel disease or&#xD;
             other bowel disease that causes chronic diarrhoea (defined as grade ≥ 2 diarrhoea&#xD;
             according to Common Terminology Criteria for Adverse Events (CTCAE)&#xD;
&#xD;
          -  Clinically significant peripheral sensory neuropathy&#xD;
&#xD;
          -  Evidence of previous acute hypersensitivity reaction, of any grade, to any component&#xD;
             of the treatment&#xD;
&#xD;
          -  History of Gilbert disease or known dihydropyrimidine deficiency syndrome&#xD;
&#xD;
          -  Recent gastroduodenal ulcer to be active or uncontrolled&#xD;
&#xD;
          -  Recent pulmonary embolism, deep vein thrombosis, or other significant venous event&#xD;
&#xD;
          -  Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled&#xD;
             anticoagulation therapy&#xD;
&#xD;
          -  Recent major surgical procedure, open biopsy, or significant traumatic injury not yet&#xD;
             recovered from prior major surgery&#xD;
&#xD;
          -  History of any disease that may increase the risks associated with study participation&#xD;
             or may interfere with the interpretation of study results.&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,&#xD;
             chronic active hepatitis B infection&#xD;
&#xD;
          -  Any disorder that compromises the patient's ability to provide written informed&#xD;
             consent and/or comply with study procedures&#xD;
&#xD;
          -  Any investigational agent within 30 days prior to inclusion&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy or placement of a central venous catheter) and/or&#xD;
             radiotherapy within 28 days prior to inclusion in the study.&#xD;
&#xD;
          -  Male or female of childbearing age who do not agree with taking adequate contraceptive&#xD;
             precautions, i.e. use contraception double barrier (e.g. diaphragm plus condoms) or&#xD;
             abstinence during the course of the study and for 6 months after the last&#xD;
             administration of study drug for women and 1 month for men&#xD;
&#xD;
          -  The patient is unwilling or unable to meet the requirements of the study.&#xD;
             Psychological, geographical, familial or sociological conditions that potentially&#xD;
             prevent compliance with the study protocol and follow-up schedule. These conditions&#xD;
             should be discussed with the patient before inclusion in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Ramirez-Daffós, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta del Mar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Punta Europa</name>
      <address>
        <city>Algeciras</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerto Real</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Cecilio</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

